TCOF1

TCOF1 Full Name

Treacher Collins-Franceschetti syndrome 1

TCOF1 Introduction

TCOF1 (Treacher Collins-Franceschetti syndrome 1) is a key developmental gene that plays a central role in craniofacial formation and ribosome biogenesis, and its dysfunction is the primary genetic cause of Treacher Collins syndrome (TCS), a rare congenital disorder characterized by distinctive craniofacial abnormalities. The TCOF1 gene encodes Treacle, a nucleolar phosphoprotein that is highly expressed during embryonic development, particularly in neural crest cells and neuroepithelial tissues responsible for forming facial structures. For researchers and clinicians investigating unexplained craniofacial malformations or genetic developmental disorders, understanding TCOF1 is essential because pathogenic variants can disrupt early embryonic processes before structural abnormalities become clinically apparent. Recent genetic studies have expanded the known TCOF1 mutation spectrum, identifying novel frameshift and splicing variants that affect Treacle protein stability, nuclear localization, and functional activity, providing valuable insights for molecular diagnosis and genetic counseling.

The primary function of TCOF1 is closely linked to nucleolar organization, ribosomal RNA synthesis, and ribosome assembly. Treacle interacts with upstream binding factor (UBF) and other components involved in ribosome biogenesis, ensuring proper maturation of ribosomal subunits required for protein synthesis during rapid embryonic growth. Loss-of-function mutations in TCOF1 reduce Treacle activity, impair ribosomal production, and trigger cellular stress responses, including activation of the p53 pathway and increased apoptosis in neural crest cells. Because cranial neural crest cells contribute extensively to facial bone, cartilage, and connective tissue development, their abnormal depletion results in the characteristic features of TCS, such as mandibular and zygomatic hypoplasia, downward-slanting palpebral fissures, external ear abnormalities, and hearing impairment. Emerging evidence also suggests that TCOF1 participates in additional biological processes, including DNA damage response regulation, telomere maintenance, and transcriptional control, highlighting its broader role in maintaining cellular stability during development.

TCOF1-related disease is most strongly associated with Treacher Collins syndrome, an autosomal dominant craniofacial developmental disorder with highly variable clinical severity. More than one hundred pathogenic TCOF1 variants have been reported, with many mutations occurring in the central repetitive domain (CRD) and C-terminal region containing nuclear localization signals (NLS). Recent functional analyses have demonstrated that newly identified TCOF1 mutations can produce truncated Treacle proteins, disrupt nuclear transport, alter RNA splicing, and reduce gene expression, confirming their pathogenic mechanisms. Beyond craniofacial manifestations, some individuals with TCS may experience hearing loss, speech difficulties, neurodevelopmental challenges, and increased risk of autism spectrum features, emphasizing the importance of comprehensive clinical management. Continued research into TCOF1-mediated pathways, including ribosome stress responses and p53-dependent apoptosis, may provide new opportunities for developing targeted therapeutic strategies for patients affected by TCOF1-associated disorders.

Alternate Names for TCOF1

TCOF1; Treacher Collins-Franceschetti syndrome 1; treacle protein; treacle; MFD1; TCOF 1; TCOF_HUMAN; TCOF1; Treacher Collins syndrome protein; Treacle; Treacle protein; OTTHUMP00000160560; OTTHUMP00000224041; OTTHUMP00000224042; OTTHUMP00000224043; OTTHU

• 1.Chen Y, et al.; Identification of novel TCOF1 mutations in Treacher Collins syndrome and their functional characterization. Orphanet J Rare Dis. 2025, 20(1):184.
  2.Jiang Z, et al.; Deciphering TCOF1 mutations in Chinese Treacher Collins syndrome patients: insights into pathogenesis and transcriptional disruption. Orphanet J Rare Dis. 2025, 20(1):57.